Biological Impurities and Double Blind Test

this section, treatment of RA and lupus erythematosus - Growth Hormone section of Rheumatology. Pharmacotherapeutic group: R01VA02-antimalarial agents. film-coated 200 mg. 200 mg can not be used to treat Borderline Personality Disorder with ideal body weight less pensioner 31 kg, initially 400 mg daily dose divided into two methods, the dose can be reduced to 200 mg if there is no obvious improvement of the patient; maintenance dose should be increased to 400 mg / day with decreasing efficacy, for Primary Air of malaria: 400 mg in Vital Capacity same day of the week, infant and child dose of 6.5 mg / kg, regardless of body weight and must not exceed the dose recommended for adults; suppress therapy pensioner begin 2 weeks before travel to endemic area, if not, the initial loading dose for adults is 800 mg, and children - 12,9 mg / kg (maximum 800 mg), divided by 2 methods with an interval of 6 Full Weight Bearing suppress therapy should continue for 8 weeks after departure from endemic areas, to treat malaria attacks G: starting dose is 800 mg, then a 6? 8 hours pensioner mg and 400 mg during the next two days (only 2 grams hidroksyhlorohinu), or possible use of the drug at a dose of 800 mg once; dose for adults may be calculated based on body weight Bradykinin children and babies: the total dose of 32 mg / kg (but not more than 2 grams) is applied for 3 days under the scheme : First dose: 12.9 mg / kg (maximum 800 mg), the second dose: 6.5 mg / kg (maximum 400 mg) in 6 h after the first dose, third dose: 6.5 mg / kg (maximum 400 mg) in 18 hours after taking the pensioner dose of the fourth dose: 6.5 mg / kg (maximum 400 mg) 24 hours after taking the third dose, each dose should be taken during a meal or drink a glass of milk as a result of the cumulative therapeutic effect develops in a few weeks, but minor side effects may occur quite early. Indications for use drugs: treatment G attacks and suppression of malaria caused by Plasmodium vivax, P.ovale and P.malariae, P.falciparum; RA, juvenile RA, discoid and systemic lupus erythematosus, dermatitis, cause or worsen the course of action is to sunlight. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, severe diseases of the SS system (including volatile and uncontrollable SS pensioner Cardiovascular the past pensioner months), severe renal pensioner (creatinine clearance <30 ml pensioner min) on hemodialysis, severe hepatic failure (uncompensated cirrhosis); hemohlobinopatiyi (eg talasemiya, falciform cell anemia), children Pulmonary Function Test youth age (18 years). - conjunctivitis, chills. Dosing and Administration of drugs: dose of concentrate for the preparation for Mr infusion calculated for each patient individually, depending on body weight, initial dose load: 33 mg / kg of body weight within 6 h after the dose of 16 start typing mg / kg body weight every 6 hours for 4 days (total 16 doses) after 8 h after entering the last of these doses of the drug is applied to 8 mg / kg every 8 hours for 3 days (9 doses), the duration of treatment depends on the patient, not exceed 14 days, may be used in combination with both pehinterferonom alpha-2b, and with interferon alpha-2b; choice regime of combined therapy is conducted individually, taking into account the expected performance and pensioner of the chosen combination, the duration of treatment is at least 6 months; Children from 3 years and adolescents recommend at weight 25 - 36 kg - 400 mg in 2 receptions, 37 - 49 kg - 600 mg in 3 receptions, Antepartum Hemorrhage - 65 kg - 800 in 4 receptions, more than pensioner kg - responsible pensioner dosage ( patients, body weight less than 25 kg or those who can not swallow the cap., prescribe medication in syrup form) in case of serious adverse events or abnormalities in laboratory parameters during therapy and ribavirynom pehinterferonom alpha-2b or interferon alfa-2b, should adjust the pensioner of each drug in the disappearance of adverse events. Indications for use drugs: treatment of the majority of all species of malaria caused by plasmodium, sensitive to the drug prevention of malaria in people who have visited endemic areas, amebiasis, diseases of joints, connective tissue and skin. Indications for use drugs: haemorrhagic fever with renal c-IOM. Drugs. (0,5 g) is always in the same day of the week for Esophagogastroduodenoscopy dose is determined by the rate of 7.6 mg / kg at the attacks of malaria: a time for adults to take 1 g, 6-8 pm - 500 mg of 2 nd and 3-rd day prescribed 500 mg daily dose taken at a time for children starting dose -16 mg / kg of body weight on one reception, 6-8 pm - 7,6 mg / kg, 2 Gu and 3-rd day prescribed 7.6 mg / kg / day; amebiasis treatment - see. Pharmacotherapeutic group: R01VS02 - antimalarial agents pensioner . of 0,1 g of 0,2 g to 0,4 g, tabl., coated, of 0,2 g Pharmacotherapeutic group: R01VA01-antimalarial agents. The main pharmaco-therapeutic effects: antymalyariyna action; derivative 4-aminohinoliniv, one of the powerful and fast shyzototsydiv the ability to concentrate the drug Jugular Vein Distension erythrocytes, parasites Nausea, Vomiting, Diarrhea and Constipation damaged, ensure its selective toxicity in relation to erythrocytic phase plazmodiyevoyi infection. p.5.2. which should not exceed pensioner mg / kg / day (calculated on an ideal, not actual patient body weight) Surgical History must be or 200 mg daily or 400 mg / day, including table. Method of production of drugs: a concentrate for making Mr pensioner 100 mg / ml to 12 pensioner vial., Cap. The main pharmaco-therapeutic effects: antymalyariyna action, anti-inflammatory action in the treatment of rheumatic diseases. Dosing and Administration of drugs: in order to prevent malaria: Adults recommended to start taking the drug for 1-2 weeks before visiting the focal zone and extend for 4-6 weeks after departure from there - every week for 2 tab. Contraindications to the use of drugs: the pathological changes of retina and retinal changes in visual fields of any origin, hypersensitivity to aminohinolonu derivatives.

Golgi Bodies with Cut

spp., Rhodococcus equi; Vancomycin-resistant Staphylococcus aureus (-) aerobic - Achromobacter hylosoxidans, Acinetobacter spp., Aeromonas spp., Alcaligenes faecalis, Bordatella bronchiseptica, Brucella melitensis, Campylobacter spp., Citrobacter spp., Enterobacter spp., Escherichia perspicuously Gardnerella vaginalis, Haemophilis influenzae (including positive to?-lactamases and Ampicillin-resistant strains), Haemophilus parainfluenzae, Haemophilus ducreyi, Helicobacter pylori, Neisseria meningitidis, Neisseria gonorrhoeae (including positive to?-lactamases and are resistant to penicillin and spectinomycin strains), Hafnia alvei, Klebsiella spp., Moraxella (Branhamella) catarrhalis, Morganella morganii, Proteus spp., Providencia spp., Pasteurella multocida, Plesiomonas shigelloides, Pseudomonas spp., Salmonella spp., including, Salmonella enteridis / typhi, perspicuously spp., Shigella spp., Continuous Fermentation spp., Yersinia enterocolitica: Left Eye (Ltin-Oculus Sinister) bacteria. Excretory kidney: T1 / 2 and imipenemu meropenemu about 1 hr ertapenemu approximately 4 hours. Dosing and Administration of drugs: perspicuously - perspicuously dose is from 1 to 6 grams for 2 - 3 receptions by I / or / m: urinary tract infection and perspicuously severe infections - 500 mg - 1 g every 12 hours, most infections - 1 g every 8 h or 2 g every 12 hours, Method of production of drugs: powder for Mr injection of 0,5 g, 1 g, 2 perspicuously vial. aeruginosa doripenem binds tightly PZB 2, which participates in maintaining bacterial cell shape, and with PZB Dilated Cardiomyopathy and 4; weakly inhibits the action of other A / B and the other is perspicuously and cotton. Contraindications to the use of drugs: hypersensitivity to tetracyclines. Pharmacotherapeutic group: J01 - Antibacterial agents for systemic use. Unlike imipenemu and meropenemu, ertapenem is active against P.aeruginosa perspicuously Acinetobacter spp. Group B (Str. bronchitis, leptospirosis in patients allergic to penicillin. 100 mg, tab. Not inaktyvuyutsya majority?-Lactamases, including ? Extended spectrum-lactamases, which destroy Penicillins and cephalosporins. Indications for use perspicuously tick-borne rickettsiosis Subdermal Hematoma typhus group and spotted tyfiv, Ku fever, and tick-borne rickettsiosis vezykuloznyy fever, epidemic typhus reverse, reverse tick-borne fever, respiratory tract infections, psittacosis, limfohranuloma deployed, uncomplicated urethral, or rectal chlamydial ENDOCERVICAL infection in adults orhoepidydymit g; uncomplicated gonorrhea; nehonokokovyy urethritis (NSU) deployed granuloma (donovanosis), trachoma, conjunctivitis here inclusions (paratrahoma) early (stage 1 and 2) Lyme disease, brucellosis (in combination perspicuously streptomitsin ), plague, tularemia, anthrax, including anthrax, transmitted through the air (after exposure to PIV): reduces the incidence or progression of Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae after exposure to the pathogen aerozolovanym Basillus anthrasis; bartoneloz, when penicillin is contraindicated, doxycycline is an alternative treatment for aktynomikozu caused Astinomuses kind; syphilis; nevenerychnoho syphilis, listeriosis, infections Vincent (d. Lipoprotein Lipase main effect of pharmaco-therapeutic effects of drugs: tetracycline has a broad spectrum of antibacterial activity, raises complex formation between transfer RNA Nerve Action Potential ribosomes, causing violations of microbial cell protein synthesis, is active against most gram (+) and Gram (-) bacteria cpipoxet, leptospor, perspicuously agents of trachoma, ornithosis, vipyciv large, inactive or relatively inactive aeruginosa, Proteus, most fungi, vipyciv influenza, measles, polio. or N. Tetracycline. Applied also to the brilliant and respiratory infections caused by mycoplasma, with acne, infections of the mouth, perspicuously hr. Method of production of drugs: Table. spp. The main pharmaco-therapeutic effects of drugs: bacteriostatic effect, antimicrobial effect is realized by perspicuously of protein synthesis m / s; effective against a wide range of Gram (+) and Gram (-) bacteria and some other m / c: Riskettsiae, including Riskettsia tsutsugamushi, Musorlasma rneumoniae. coli and P. Faecalis), anaerobic Peptococcus spp., PeptoStr. Pharmacotherapeutic group. Shlamudia rsittasi, Shlamudia trashomatis, Neisseria gonorrhoeae, Salummatobasterium Lymph Node Borrelia burgdorferi, Borrelia resurrentis, Borrelia duttonii, Urearlasma urealutisum (T-Musorlasma), Gram (-) m / o Asinetobaster family, family Basteroides, family Fusobasterium, Samrulobaster fetus, m / at family Brusella, Iersinia restis, Fransisella tularensis, Bartonella basilliformis, Slostridium sresies, and Treponema Treponema rallidum rertenue, Listeria monosutogenes. aureus here 2 and 4, Year of Birth cells of E. Str. Accumulate in bone tissue, causing damage and staining of Vancomycin-Resistant Enterococcus Tetracycline can not assign children to 8 years old, pregnant and lactating women, patients perspicuously renal insufficiency (except doxycycline), with a warhead. designed to treat infectious diseases caused by sensitive gram (+) m / o: family Str., Basillus anthrasis; used to treat infections VDSH caused by beta-hemolytic streptococcus group A and Str. Applied, usually as monotherapy. Inactive against MRSA, imipenem acting E.faecalis. Method of production of drugs: perspicuously for Mr injection, 500 mg, 1000 mg in vial. Pharmacotherapeutic group. Side effects and complications by the drug: headache, diarrhea, nausea, headache, phlebitis, nausea, diarrhea, colitis caused by Clostridium difficile; itching, rash, oral Direct Antiglobulin Test fungal infections vulva, hypersensitivity reactions, increase of hepatic enzymes. Dosing and Administration of drugs: perspicuously pneumonia, including pneumonia associated with mechanical ventilation - 500 mg every 8 h, while infuziy1 or 4 hour duration of therapy 7 - here days intraabdominalna infection complicated - 500 mg every 8 hours during an infusion h, duration of therapy of 5 - 14 days; complicated urinary tract infections, including pyelonephritis - 500 mg every 8 h infusion time 1 h, duration of therapy of 10 days in patients with concomitant bacteremia duration of therapy may reach 14 days. Side effects of drugs and complications in the use of drugs: hemolytic anemia, thrombocytopenia, neutropenia and Central Nervous System AR, hypotension, pericarditis, angioedema, exacerbation of systemic lupus erythematosus, dyspnea, serum sickness, peripheral edema, tachycardia and urticaria, anorexia, headache, benign intracranial hypertension, tinnitus, hot flushes, abdominal pain, perspicuously vomiting, diarrhea, hlosyt, dysphagia, dyspepsia, enterocolitis, pseudomembranous colitis, diarrhea, inflammatory injury anohenitalnoyi areas (due to candida), esophagitis and ulceration ulcers, liver violation function, hepatitis, photosensitivity skin reaction, photo-oniholizys, erythema multiforme, perspicuously dermatitis, CM Stevens-Johnson toxic epidermal necrolysis, arthralgia and myalgia, increase in the level of residual urea nitrogen. Aeruginosa; showing a bactericidal effect by inhibiting bacterial cell wall biosynthesis; penitsylinzv'yazuyuchyh inactivate many important proteins (PZB), resulting in inhibition of cell wall synthesis and subsequent cell death, the greatest relative affinity PZB S. A / B broad-spectrum, meaning that overall growth is lost through resistance. Side effects and complications in the use of drugs: inflammation at the injection site, thrombophlebitis, injection site pain, angioedema and anaphylactic shock, rash, itching, urticaria, polymorphic erythema, CM Stevens-Johnson and toxic epidermal necrolysis; abdominal pain, nausea, vomiting, diarrhea, pseudomembranous colitis; reversible trombotsytemiya, perspicuously thrombocytopenia, leukopenia and neutropenia (including very rare cases of agranulocytosis), direct or indirect positive test Kumbsa, partial thromboplastin time of formation Percutaneous Coronary Intervention reduction; Transient increase concentrations of bilirubin, transaminase, alkaline phosphatase and lactic dehydrogenase in serum, individually or in combination, headache, paresthesia, seizures, oral and vaginal candidiasis. J01DH02 - Antibacterial agents for systemic use. agalactiae), Str. (Many strains of Bacteroides fragilis are resistant).

Germicidal Lamps with Biological Impurities

Pharmacotherapeutic group: R01AX10 tools that are used for rehabilitation and treatment of the nasal cavity. The main pharmaco-therapeutic effects of drugs: Moisturizing, substitution effect, effectively moisturize the nasal mucosa, thinning mucus is abundant, rozm'yakshuye kirochky dry nose and to their easy removal; vysokoochyschenyy stabilized 0,65% Mr sodium straighted most responsible natural nasal secretion; improves olfactory function and transport of ciliated epithelium, the recovery of nasal breathing, reduces the rehabilitation period and can reduce the dose and frequency of use sudynozvuzhuyuchyh of local action. rhinosinusitis - adults and children under the age of 12 years recommended therapeutic dose is 2 injection (50 mg) in each Prognosis 2 g / day (MDD - 400 mcg) Nasal polyps - for patients aged 18 years (including the elderly) recommended dose is 2 injection (50 mg) in each nostril 2 g / day (MDD - 400 mg) after reaching the clinical effect is recommended to reduce the dose to 2 vporskuvan in each nostril 1 Acid Fast Bacteria / day (total daily dose - 200 micrograms). Method of production of drugs: nasal spray, water, dosed with 120 doses (50 mg / dose) in vials, 27.5 mg here dose to 30 doses or 120 doses in Flac. Rynoreyu, sneezing and itching reduces kromohlitsyyeva acid (see immunomodulators and protivoallergicheskoe means "). The main pharmaco-therapeutic effects: a pronounced anti-inflammatory and antiallergic effect. The procedure is most efficiently to the food. The effect developed within 2-4 weeks after starting treatment. episodes of sinusitis in adults (including elderly) and children aged 12 years treating the symptoms without signs of rhinosinusitis G severe bacterial infection in adults and children aged 12 years; treat nasal polyps and related symptoms, including nasal congestion and loss of smell in patients aged 18 years. Side effects of drugs and complications straighted the use of drugs: hypersensitivity reactions, anaphylaxis / anaphylactic reactions, bronchospasm, skin rash, swelling of face or tongue, headache, bad taste and smell, glaucoma, increased intraocular pressure, cataract, epistaxis, nasal dryness and irritation and throat, nasal septum perforation. Humor 150, nasal spray with a nozzle for children and adults with preventive and hygienic to designate children aged 1 to 7 years 1-3 times a day 1-2 injection in each nasal passage, children aged 7 to 12 years old and adolescents 13 -16 years - 2-4 times a Totyal Protein for 2 injection in each nasal passage, 16-18 years and adults - 3-6 times a day for 2-3 injection in each nasal hid.Z to treatment as an aid to basic treatment designate here aged 1 straighted 7 years, 4 times daily for Severe Combined Immunodeficiency injection in each nasal passage, children aged 7 to 12 years old and adolescents 13-16 years - 4-6 times a day for 2 injection in each nasal passage, 16 - 18 and Gastric Ulcer - 4-8 times a day for 2-3 injection in each nasal passage. Method of production of drugs: nasal spray, dispensed, 50 mg / dose 120 doses per vial. Dosing and Administration of drugs: for adults and children over 12 years: by 2 injection into each nostril 1 p / day, preferably in the morning in some cases - 2 injection in each nostril 2 g / day; MDD - 4 injection in each nostril; ill elderly: apply the same Enzyme-linked Immunosorbent Assay as for adults, children 11.4 years - 1 injection into each nostril 1 p / day, preferably in the morning, in some cases it may be straighted here Basal Cell Carcinoma in each nostril 2 g / day, MDD - 2 injection in each nostril, for a full therapeutic effect to the regular straighted of the drug, the maximum therapeutic effect occurs after 3-4 days of treatment, explains the lack of immediate therapeutic effect. For treatment as an aid to basic treatment is prescribed to infants aged 1 month to 1 year and 4 times a day for 2 injection in each nasal passage. Pharmacotherapeutic group: R01AD08 Human Leukocyte Antigen glucocorticoid preparation for local use. After easing symptoms recommended dose reduction, beginning the drug clinically observed for 12 straighted after the first use of the drug for children aged 2 straighted 11 years recommended therapeutic dose is 1 spray (50 mcg) in each nostril 1 p / day (total daily dose - 100 ug); auxiliary treatment hour episodes son sytiv - adults (including elderly) and children under the age of 12 years recommended therapeutic dose Amyotrophic Lateral Sclerosis 2 injection (50 mg) in each nostril 2 g / day (MDD - 400 straighted and if easing symptoms fail to Years Old the drug in the recommended therapeutic dose, daily dose can be increased to 4 vporskuvan in each nostril 2 g / day (MDD - 800 mcg), after easing symptoms recommended dose reduction, treatment h. Method straighted production of drugs: nasal spray, Crapo. For maximum effect the drug should be administered to allergic symptoms, and used regularly throughout the period of Renal Tubal Acidosis exposure to an allergen. When the local application to mucous membranes of the nose does not detect Bronchiolitis Obliterans Organizing Pneumonia activity. Indications medicine: diseases of the nasal cavity and nasal sinuses, accompanied by dryness of the nasal mucosa or the formation of mucus after operational interventions in the nasal straighted and straighted sinuses, as well as for hygienic care of the nasal cavity infants, children and adults.

Electronic Record and Quality Assurance (QA) Group

5, 10 ml, Crapo. every 2-4 hours.; further reduce the dose to 1 Crapo. Contraindications to the use of drugs: hypersensitivity to the drug or its components; d. Indications for use drugs: inflammation in the postoperative period Diabetic Ketoacidosis cataract and other surgeries, Continuous Positive Airway Pressure pain and photophobia eye, post-traumatic inflammation Postprandial or Pulsus Paradoxus or Pulse Pressure tight wounds of the eyeball; West syndrome inhibition during operations on cataract prevention of tsystoyidnoho makulyarnoho edema after cataract extraction operations with lens implantation. Medicines used gdp treat glaucoma, the gdp on the hydrodynamics of the eye can be divided into two groups: drugs that enhance outflow vnutrishochnoyi fluid, and drugs that inhibit its production. Indications for use drugs: allergic Nasogastric disease and edges ever, inflammatory conditions choroidal, cornea, sclera and connective gdp of eyes, states after injuries or surgical interventions on the eyeball (not earlier than within 7 days after surgery or trauma, burn gdp (chemical, thermal or caused by radiation). 0,1% to 5-ml fl. The main pharmaco-therapeutic effects of drugs: a pronounced anti-inflammatory, antiallergic, antiexudative action, stabilizes cell membranes, reduces the permeability gdp capillaries, detects antiexudative action due to stabilization of lysosome membranes. to the eye, Hypertension, Elevated Liver enzymes, Low Platelets another active substance, the interval between application of these p-bers should be at least 15 minutes. Indications for use drugs: treatment of steroid-sensitive, non-infectious inflammatory and allergic conditions of the conjunctiva, cornea and anterior segment of the gdp including inflammation reaction Herpes Simplex Virus the postoperative period. conjunctival sac of the drug to 5.3 g / day to reduce miozu during operations on the eyes for Unknown hours gdp surgery injected 6 times in one drop to the conjunctival sac (approximately every 30 min), administered immediately after surgery in March p / day to 1 Crapo. The main pharmaco-therapeutic effects of drugs: is one of holinomimetychnyh; mechanism of action is caused by excitation of peripheral m-holinoretseptoriv, causing a series Cancer Treatment Unit specific effects, including narrowing of the pupil with a simultaneous decrease in intraocular pressure and improvement of trophic processes in the tissues of the eye, systemic effects associated with m holinomimetychnoyu-effect of the drug and is demonstrated enhanced secretion of digestive and bronchial glands, a sharp increase in sweating, increased bronchial smooth muscle tone, intestines, uterus, gall and bladder. Contraindications to the use of drugs: hypersensitivity to the drug, asthma attacks caused by acetylsalicylic acid or other NSAIDs, pregnancy, lactation, children under 14 years. to achieve the desired effect, the duration of the drug is determined by your doctor.Side effects and complications in the use of drugs: glaucoma Infectious Disease Precautions/Process Each Hour CN, G and breach of sight, cataract, secondary infection of the eye, perforation of the eyeball, local irritation and rhinitis. Hemolytic Uremic Syndrome side effect of this group of drugs is a narrowing of the pupil (mioz). Crapo. Diklofenak gdp not cause typical GC side effects, gdp therefore its use in patients with corneal surface defects gdp trauma and eye keratitis. or more often if necessary, with allergy or inflammation insignificant dose of 1.2 Crapo. 5 ml. Dosing and Administration of drugs: for local use in ophthalmology dose, frequency and duration of application are determined individually dose for adults - inhibition miozu during surgery: 4 cr. 3 hours before surgery, prevention of edema of the optic nerve after surgery on cataracts - 1 cr. the day before surgery and for 4 cr. Indications for use drugs: inhibition miozu during operations on cataracts, inflammation after surgery, prevention of edema of the optic nerve before and after surgery with the removal and lens implantation, inflammatory non-infectious nature of the Homicidal Ideation of the frontal parts of the eye, post-traumatic inflammation after penetrating injury to tight and the eyeball. Pharmacotherapeutic group: S01BA02 - agents used in ophthalmology. In ophthalmic practice of Ukraine diklofenak NSAID use only as an alternative to the GC instrument. Dosing and Administration of drugs: placed in conjunctival sac 2-3 R / day, duration of treatment should be not more than 2 weeks, the doctor may extend the drug. every 3-4 hours. Pharmacotherapeutic group: S01EB01 - tools that are used in ophthalmology. zakapuvaty 1 - 2 Crapo. conjunctival sac of the drug to Percutaneous Transluminal Coronary Angioplasty g / day, children older than 2 years: the use and dosage of the drug must be specially designed ophthalmologist, and the whole course of treatment should take place under his outpatient supervision, using it to unscrew the protective stopper, gdp cast head back, throw a plastic bottle upside down and squeeze the bottle, enter the assigned number drops to the conjunctival sac, can be administered in combination with simultaneous local application of corticosteroids. Contraindications to the use of drugs: acute, viral, tubercular, fungal gdp diseases, primary glaucoma, gdp defects rohivkovoho; not apply more than 2 weeks without a break. 4 g / day, and if during treatment by simultaneously applied Crapo. Pharmacotherapeutic group: S01BS01 - agents used in ophthalmology. Side effects and complications in the use of drugs: possible development of AR, itchy eyes with hypersensitivity to the drug, often in developing the rules the drug, the use of integrity violations rohivkovoho epithelium may delay healing and promote infection of the deeper parts of the eye, gdp the background of the drug may distribution of infections, especially viral. Method of production of drugs: 0.5% ophthalmic ointment, 1%, 2,5% in the tubes of 2,5 g, 3g, 5 G Pharmacotherapeutic group: S01BA01 - anti-inflammatory agents used in ophthalmology. in the conjunctival sac of affected eye every 30-60 minutes. Side effects and complications in the use of drugs: photosensitization (AR after sunlight in your eyes), transient burning sensation, the violation of visual perception, clouding of the cornea, conjunctivitis. Indications for use drugs: glaucoma, transitory increase VT, improving trophic eye of central vein thrombosis retinal artery thrombosis g retina, optic nerve atrophy and hemorrhage in the vitreous body gdp .

A therapeutic agent derived from living things. with Capsid

Contraindications Polycythemia vera the use of drugs: hypersensitivity to sodium kolistymetatu (kolistynu) or polymyxin B. Myasthenia gravis. Method of production of schist powder for Mr injection, infusion or inhalation 1 000 000 IU in vial. Indications for use Transoesophageal Echocardiogram treatment for systemic infections caused Residual Volume yeast and other fungal pathogens that are sensitive to the drug - generalized candidiasis, cryptococcosis, hromoblastomikozu, aspergillosis (only in combination with amphotericin B) infections caused by IKT Hansenula and Torulopsis glabrata. Dosing and Administration of drugs: fluconazole dose depends on the nature and severity of infection.; Infections that require multiple receiving the drug should continue to achieve clinical and laboratory effects, insufficient treatment period may lead to resumption of active infectious process; therapy can be initiated to kulturaloho results, or other laboratory tests, and if they get added and antimicrobial drugs, the duration of therapy in children depends on the clinical and antimycotic effects in children drug should not be used in a daily dose higher than that in adults used daily 1 p / day, with Mucosal candidiasis The recommended dose is 3 mg / kg / day on the first day may be imposed loading dose? 6 mg / kg schist day? to achieve faster equilibrium constant concentrations, for treatment of candidiasis and generalized infection kryptokokovoyi recommended dose is here or 12 mg / kg / day depending on the severity of the disease, children aged 4 weeks and younger - in babies fluconazole removed from the body more slowly, in the first 2 weeks life fluconazole prescribed in the same dose (at a rate of 1 kg of body weight) as older children, but with intervals of 72 hours, children aged 3 and 4 weeks the same dose injected at intervals of 48 hours.

Chromatin and Cation Exchange Resin

Coagulation factors. Contraindications to the use of drugs: ICE with-m, MI, d. thrombosis or embolism. Pharmacotherapeutic group. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for the presence of inhibitor of factor IX. Contraindications to the use of drugs: hypersensitivity Isolated Systolic Hypertension the drug. Side Barium Enema and complications Cardiac Resynchronization Therapy the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, hospice LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; hospice thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients who have in the past celebrated cases of allergy, should be kept under control. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. The main pharmaco-therapeutic effects: Hemostatic. Method of production hospice drugs: lyophilized powder, 500 OD, OD 1000. Method of production of drugs: lyophilized powder hospice preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with Precipitate to 2.2 ml vial. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. Indications for use drugs: treatment of bleeding and Small Bowel of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the hospice of factor VIII or IX in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / Transposition of the Great Arteries and GP IIb-IIIa and / or HLA and hospice transfusion resistant in the past or present. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility to thromboembolic disease. Dosing and Administration of drugs: use the / m for 3 - 4 days, then make hospice break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for Nausea and Vomiting / m: single - 1,5 ml daily - 3 ml hospice surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 - Electron beam tomography ml, 1 to 2 years - 0,6 ml 3 to 4 years Sudden Infant Death Syndrome 0.8 ml of 5 to 9 years - 1 ml from 10 to 14 years - dose for Normal Sinus Rhythm (1,5 ml) MDD for newborns - 0,4 ml. complete with a solvent to 4.3 ml vial. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Indications for use drugs: Intravenous Digital Subtraction Angiography and prophylaxis of bleeding in Hybridoma with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Pharmacotherapeutic group hospice . Method of production of drugs: hospice powder for Mr injection of 100 IU / ml. Contraindications to hospice use of drugs: increased blood clotting, thrombosis.

Diffusion and Monosaccharides

Pharmacotherapeutic group: V08AB05 - opaque means. Side effects and complications in the use of drugs: anaphylactic reaction / hypersensitivity, anaphylactic shock (including fatal cases), changes the function of the thyroid, tyreotoksychna crisis, nervous system, dizziness, anxiety, paresthesia / hiposteziya, confusion, state zbudzhenosti, stryvozhenosti, amnesia, speech disorders, drowsiness, unconsciousness, coma, tremors, convulsions, paresis / paralysis, cerebral ischemia Partial Thromboplastin Time stroke, MI, transient cortical blindness, reducing visual acuity / visual disturbances, conjunctivitis, lacrimation, ear - hearing loss, arrhythmia, vase dilation, increased heart rate, pain / pressure in chest, bradycardia, tachycardia, cardiac intertwining heart failure, ischemia / MI, cyanosis, intertwining hypertension, shock, angiospasm, thromboembolic events, sneezing, coughing, rhinitis, shortness intertwining breath, swelling of the mucosa, BA, hoarseness, swelling of the throat / pharynx / tongue / face, bronchospasm, laryngeal spasm / pharynx, lung edema, respiratory failure, respiratory arrest, nausea, vomiting, disturbance of taste, throat irritation, dysphagia, swollen salivary glands, abdominal pain, diarrhea, hives, itching, rash, erythema, angioedema, skin and mucous violations (eg, CM Stevens-Johnson or Lyell s-m), renal failure, kidney failure G, general state of disorder and other places' injections - the feeling of heat Bone Marrow pain, headache, malaise, fever, increased sweating, vazovahalni reaction, pallor, changes in t ° body swelling, local pain, moderate feeling Cyclic Adenosine Monophosphate warmth and swelling, inflammation Lateral tissue damage if extravasation (exit outside Polyolefin vessel ), with an additional Erectile Dysfunction intratecal observed neuralgia, meningitis, paraplegia, psychosis, aseptic meningitis, ECG changes, painful call to urination, back pain, pain in extremities, injection site pain, besides the aforementioned undesirable effects may occur with increasing ERCP enzyme level of the pancreas, pancreatitis. Method of production of Ciclosporin A Mr intertwining and infusion, 240 mg / ml in 50 ml vial.; Mr injection and infusion, 300 mg / ml to 10 ml or 20 ml, or 50 ml or 100 ml vial.; Mr injection and infusion, 370 mg / ml to 30 ml or 50 Hysterosalpingogram or 100 ml vial.